Fiduciary Financial Group LLC Has $372,000 Stock Holdings in Novartis AG (NYSE:NVS)

Fiduciary Financial Group LLC decreased its holdings in shares of Novartis AG (NYSE:NVS) by 9.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,595 shares of the company’s stock after selling 384 shares during the period. Fiduciary Financial Group LLC’s holdings in Novartis were worth $372,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Nexus Investment Management ULC acquired a new position in Novartis during the first quarter worth $25,000. Raiffeisen Bank International AG acquired a new position in Novartis during the fourth quarter worth $25,000. Human Investing LLC acquired a new position in Novartis during the fourth quarter worth $25,000. Union Bancaire Privee UBP SA acquired a new position in Novartis during the fourth quarter worth $27,000. Finally, Park Square Financial Group LLC acquired a new position in Novartis during the fourth quarter worth $30,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on NVS. Morgan Stanley initiated coverage on shares of Novartis in a report on Wednesday, February 12th. They set an “underweight” rating on the stock. BNP Paribas upgraded shares of Novartis to a “strong-buy” rating in a report on Tuesday, April 15th. Finally, UBS Group reiterated a “neutral” rating on shares of Novartis in a report on Thursday, February 13th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $123.38.

Novartis Stock Performance

Shares of NVS stock opened at $118.59 on Wednesday. The company has a market cap of $250.52 billion, a P/E ratio of 20.17, a P/E/G ratio of 1.70 and a beta of 0.59. The firm has a 50-day moving average of $110.89 and a 200-day moving average of $106.78. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. Novartis AG has a one year low of $96.06 and a one year high of $120.92.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.16. The company had revenue of $13.23 billion during the quarter, compared to analyst estimates of $12.92 billion. Novartis had a net margin of 23.56% and a return on equity of 37.24%. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.80 earnings per share. Equities research analysts forecast that Novartis AG will post 8.45 EPS for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.